You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 27, 2024

Details for Patent: 6,435,372


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,435,372
Title: Delivery system for a medicament and method for the assembly thereof
Abstract:An indicating device for use with a dispensing device that dispenses metered dosages of a medicament from a container having a valve moveable between an open and closed position. In a preferred embodiment, the container is reciprocally moveable within the housing along a longitudinal axis. The housing preferably has a well adapted to receive a valve stem and an exhaust port. The well communicates with the port such that the metered dosage of medicament is dispensed through the port when the valve is moved to the open position. An indicator assembly comprises an indicator member that includes dosage indicia visible to a user. In a preferred embodiment, the indicator assembly is provided in an indicator module. A method for dispensing measured dosages is also provided, along with a kit capable of being assembled as an inhalation device. A delivery system having a key member and a key entry passageway is also provided.
Inventor(s): Blacker; Richard (London, CA), Engelbreth; Daniel K. (London, CA), Schmidt; James N. (London, CA)
Assignee: 1263152 Ontario Inc. (London, CA)
Application Number:09/954,428
Patent Claim Types:
see list of patent claims
Use; Delivery; Device;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of a US Patent: A Detailed Analysis of US Patent 6,435,372

Introduction

When navigating the complex world of patents, understanding the scope and claims of a specific patent is crucial for inventors, businesses, and legal professionals. This article will delve into the details of US Patent 6,435,372, providing a comprehensive analysis of its scope, claims, and the broader patent landscape.

What is a Patent?

A patent is a form of intellectual property that grants the patent holder the exclusive right to make, use, and sell an invention for a specified period, typically 20 years from the filing date of the patent application. The U.S. Patent and Trademark Office (USPTO) is responsible for granting these patents[2].

US Patent 6,435,372 Overview

To analyze US Patent 6,435,372, we need to look at its title, abstract, and claims.

Title and Abstract

While the specific details of US Patent 6,435,372 are not provided in the sources, a typical patent includes a title and an abstract that summarize the invention. For example, if the patent is related to a technological innovation, the title might reflect the core of the invention, and the abstract would provide a brief description of its purpose and functionality.

Claims

The claims section is the most critical part of a patent as it defines the scope of the invention. Claims are statements that describe the invention in a way that distinguishes it from prior art. There are two main types of claims: independent claims and dependent claims.

  • Independent Claims: These claims stand alone and define the invention without reference to other claims.
  • Dependent Claims: These claims refer back to and further limit an independent claim.

Analyzing the Claims of US Patent 6,435,372

Claim Structure

Each claim in a patent is carefully crafted to ensure it is clear, concise, and legally enforceable. Here is a hypothetical example of how claims might be structured:

Claim 1: A method for [briefly describe the method], comprising:
    - Step A: [describe the first step];
    - Step B: [describe the second step];
    - Step C: [describe the third step].

Claim 2: The method of claim 1, wherein [further limit the method].

Claim 3: A system for [briefly describe the system], comprising:
    - Component A: [describe the first component];
    - Component B: [describe the second component].

Claim Scope

The scope of the claims determines what is protected by the patent. Broader claims may cover a wider range of variations, while narrower claims are more specific but may offer less protection. The scope is crucial for determining infringement and for defending the patent against challenges.

Patent Landscape and Trends

Allowance Rates

The probability of receiving a US patent has decreased over time, particularly in certain technology fields. For instance, between 1996 and 2005, the allowance rate for patent applications decreased substantially, especially in fields like "Drugs and Medical Instruments" and "Computers and Communications"[1].

Patent-Eligible Subject Matter

The USPTO and the courts have been refining what constitutes patent-eligible subject matter. Section 101 of the Patent Act sets out four categories of patentable inventions: processes, machines, manufactures, and compositions of matter. However, recent judicial decisions, such as the Alice/Mayo test, have introduced additional hurdles for patent eligibility, particularly for abstract ideas and methods of organizing human activity[5].

Impact of Alice/Mayo Framework

The Alice/Mayo framework has significantly impacted the patent landscape, especially for AI and computer-related inventions. Post-Alice, the USPTO issued new guidance in 2019 to clarify how to apply this framework, which has led to an increase in the allowance rate for AI-related patent applications. However, this guidance is not binding on courts, and its impact is still being evaluated[5].

Challenges in Patent Prosecution

Continuation Applications

Patent applicants often use continuation applications to create related applications, which can affect the overall allowance rate. The USPTO's data shows that when continuation procedures are excluded, the allowance rate for utility patent applications is approximately 55.8%[1].

Examination Time and Quality

The time and quality of patent examinations are critical factors. The USPTO has increased the time available for certain art units to ensure thorough examinations, and it has developed correctness measures to ensure compliance with statutory requirements[4].

Stakeholder Views and Legislative Developments

Stakeholders have varying views on the current patent eligibility standards. Some argue that the Alice/Mayo framework has positively affected innovation by excluding abstract ideas, while others believe it hampers innovation in emerging technologies like AI. Legislative and administrative efforts are ongoing to refine these standards and ensure they encourage innovation across different sectors[5].

Key Takeaways

  • Patent Claims: The claims section is the heart of a patent, defining the scope of the invention.
  • Patent Landscape: The probability of receiving a US patent varies by technology field and has decreased over time.
  • Patent-Eligible Subject Matter: Recent judicial decisions and USPTO guidance have refined what constitutes patent-eligible subject matter.
  • Impact of Alice/Mayo: This framework has significantly impacted AI and computer-related inventions.
  • Continuation Applications: These can affect the overall allowance rate and prosecution strategy.
  • Examination Quality: Ensuring thorough and high-quality examinations is crucial for maintaining the integrity of the patent system.

FAQs

Q: What is the typical allowance rate for US patent applications? A: The allowance rate for US patent applications is approximately 55.8% when excluding continuation procedures[1].

Q: How has the Alice/Mayo framework impacted AI-related patent applications? A: The Alice/Mayo framework initially reduced the allowance rate for AI-related patent applications, but the 2019 USPTO guidance has led to an increase in allowance rates for these applications[5].

Q: What are the main categories of patentable inventions under Section 101 of the Patent Act? A: The main categories are processes, machines, manufactures, and compositions of matter[5].

Q: Why is the scope of patent claims important? A: The scope of patent claims determines what is protected by the patent and is crucial for determining infringement and defending the patent against challenges.

Q: How do continuation applications affect the patent prosecution process? A: Continuation applications can create related applications, which can affect the overall allowance rate and the prosecution strategy of the original application[1].

Sources

  1. Carley, M., Hegde, D., & Marco, A. (2015). What Is the Probability of Receiving a US Patent? Yale Journal of Law & Technology, 17, 203-206.
  2. U.S. Patent and Trademark Office (USPTO). (n.d.). U.S. Patent and Trademark Office (USPTO). Retrieved from https://www.usa.gov/agencies/u-s-patent-and-trademark-office
  3. USPTO. (2017). Patent Claims Research Dataset. Retrieved from https://www.uspto.gov/ip-policy/economic-research/research-datasets/patent-claims-research-dataset
  4. GAO. (2016). Intellectual Property: Patent Office Should Define Quality, Reassess Processes. Retrieved from https://www.gao.gov/products/gao-16-490
  5. CRS Reports. (2024). Patent-Eligible Subject Matter Reform: An Overview. Retrieved from https://crsreports.congress.gov/product/pdf/IF/IF12563

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 6,435,372

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.